1,520 Alzheimers Headlines
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
"2 NEW THERAPIES FOR ALZHEIMER'S"
Produced by MD Health Channel
Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz

Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them!
"2 NEW THERAPIES FOR ALZHEIMER'S"
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

St. Joseph's Hospital and Medical Center



DO YOU HAVE ALZHEIMERS?
 
"HELP DR. REYES... IN HIS BATTLE TO FIND A CURE...
.HE NEEDS YOUR HELP:
YOU CAN HELP WIN THE BATTLE FOR A CURE BY JOINING A TRIAL!!"....

Stan Swartz, CEO,
The MD Health Channel



"You'll receive all medication and study based procedures at
no charge

if you qualify for one of the many trials being conducted at Barrow Neurological Institute."
 

"Dr. Reyes Changed My Life"

- John Swartz
92 Years Old
Attorney at Law
"Dr.Reyes Changed My Life "
1:18
"At 92...I had lost my will to live"
5:48
Tips on Aging
2:29
"Dr. Reyes gave me customized health care"
2:09

Patricio Reyes M.D.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute

St. Joseph's Hospital and Medical Center
"PRESERVING BRAIN FUNCTIONS "
Runtime: 50:22
Runtime: 50:22
"2 NEW THERAPIES FOR ALZHEIMER'S"
Runtime: 10:27
Runtime: 10:27
ALZHEIMER'S AWARENESS PROGRAMS
Runtime: 5:00
Runtime: 5:00
BIOMEDICAL RESEARCH IN ALZHEIMER'S DISEASE
PDF Document 850 kb

Download Free

4 TALES OF NEUROSURGERY &
A PIANO CONCERT BY DR. SPETZLER...
Plus 2 books written by Survivors for Survivors!
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute

J.N. Harber Chairman of Neurological Surgery

Professor Section of Neurosurgery
University of Arizona
TALES OF NEUROSURGERY:
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
Lou Grubb Anurism
The young Heros - kids who are confronted with significant medical problems!
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!
A 1 MINUTE PIANO CONCERT BY DR. SPETZLER

Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic

Barrow Neurological Clinics
COPING WITH DEMENTIA
 
Free Windows Media Player Click

Links
Barrow Neurological Institute

Archives
October 2006  
November 2006  
December 2006  
January 2007  
February 2007  
March 2007  
May 2007  
June 2007  
November 2007  
December 2007  
April 2008  
July 2008  
August 2008  
September 2008  
October 2008  
November 2008  
December 2008  
January 2009  
February 2009  
March 2009  
April 2009  
May 2009  
February 2010  
March 2013  
May 2013  
November 2013  
January 2014  
February 2014  
March 2014  
April 2014  
May 2014  
June 2014  
July 2014  
June 2016  
July 2016  
August 2016  
September 2016  
October 2016  
November 2016  
December 2016  
January 2017  
February 2017  
March 2017  
April 2017  
May 2017  
June 2017  
July 2017  
August 2017  
September 2017  
October 2017  
November 2017  
December 2017  
January 2018  
February 2018  
March 2018  
April 2018  
May 2018  
June 2018  
July 2018  
August 2018  
September 2018  
October 2018  
November 2018  
December 2018  
January 2019  
February 2019  
March 2019  
April 2019  
May 2019  
June 2019  
July 2019  
August 2019  
September 2019  
October 2019  
November 2019  
December 2019  
January 2020  
February 2020  
March 2020  
April 2020  
May 2020  
June 2020  
July 2020  
August 2020  
September 2020  
October 2020  
November 2020  
December 2020  
January 2021  
February 2021  
March 2021  
April 2021  
May 2021  
June 2021  
July 2021  
August 2021  
September 2021  
October 2021  
November 2021  
December 2021  
January 2022  
February 2022  
March 2022  
April 2022  
May 2022  
June 2022  
July 2022  
August 2022  
September 2022  
October 2022  
November 2022  
December 2022  
January 2023  
February 2023  
March 2023  
April 2023  
May 2023  
June 2023  
July 2023  
August 2023  
September 2023  
October 2023  
November 2023  
December 2023  
January 2024  
February 2024  
March 2024  
April 2024  

This page is powered by Blogger. Isn't yours?

Friday, July 18, 2014

 

Alzheimer's Disease Fight Focuses on Preventive Treatment

"Earlier is better" has become a mantra in the field of Alzheimer's disease. Experts are targeting the prevention or delay of memory decline more, instead of just focusing on treating patients who have the disease.

Results from one of the largest randomized prevention trial to date presented Sunday here at the Alzheimer's Association International Conference suggest why scientists are thinking this way. The trial found that intervention involving exercise, diet and other behavioral changes significantly improved overall cognitive functioning in patients after two years, compared with patients in a control group.

The trial, conducted in Finland and known as Finger, is only one of roughly 25 such studies under way, experts say. More are set to begin, examining different preventive strategies in cognitively normal people or those exhibiting mild memory problems who are at high risk for developing dementia.

Some focus on lifestyle activities and others on medications to slow or stop the ravages of the disease on brain tissue and neurons.

The largest involve thousands of participants and cost tens if not hundreds of millions of dollars funded by combination of the government, private foundations and pharmaceutical companies. The latest partnership is expected to be announced Tuesday, with Novartis AG NOVN.VX +0.37% providing significant funding to the Banner Alzheimer's Institute in Phoenix for a prevention trial starting next year likely to cost over $100 million. The National Institutes of Health is also providing over $30 million for the study.

The number of Alzheimer's sufferers in the U.S. is expected to roughly triple between 2010 and 2050, growing to 13.5 million in 2050 from 5.1 million in 2010. If the disease could be delayed by just five years, the number of people with Alzheimer's at age 65 in 2050 could be reduced by nearly six million people, according to a report published by the Alzheimer's Association in 2010.

Globally, one-third of Alzheimer's disease is related to risk factors that can be potentially changed, such as lack of education and exercise, according to a study published Monday in the journal Lancet Neurology.

"Forestalling the appearance of symptoms by five to 10 years would have a tremendous public health impact and essentially would allow people to live the rest of their lives without real symptoms," says Laurie Ryan, chief of the Dementias of Aging branch at the National Institute on Aging.

Prevention efforts are receiving more attention and financial backing in the field because of growing recognition in recent years that disease-related changes in the brain begin decades before memory problems become obvious. Treating patients once the symptoms begin may be too late to make a major impact on the disease, as demonstrated by the failure of several highly anticipated experimental treatments in recent years.

Also, a greater ability to measure the progression of the disease in the brain through the use of biological markers, such as the imaging of disease-related proteins, has made it easier to detect the subtle and slow progression of the disease in live humans. Before these biomarker tests, Alzheimer's was diagnosed solely based on clinical symptoms. (It often still is.) Its pathology in the brain could only be examined with autopsy.

However, the studies are challenging because they require following a large number of people for years.

There have been many previous prevention efforts over the past decade. Many of them were small and most failed, experts say. In 2009, at a meeting convened by the NIH to examine the state of science in Alzheimer's disease, an independent review committee found no compelling evidence to show the disease could be prevented with lifestyle interventions.

Now, however, the mood of the field is shifting toward prevention. Many experts are "cautiously optimistic" about such efforts, according to Pierre Tariot, director of the Banner Alzheimer's Institute.

Several animal studies suggest that administering treatment earlier in the disease could be helpful, according to the NIA's Dr. Ryan.

And recent data from Eli Lilly LLY -0.24% & Co.'s clinical trial of its experimental compound solanezumab showed that though the compound failed overall to improve cognition in people with Alzheimer's, there was evidence that participants with more mild symptoms of the disease did benefit.

The Finger trial presented Sunday randomly assigned 1,260 people ages 60 to 77. Some went to a control group and were given basic health advice. Others underwent an intervention that incorporated diet and exercise, cognitive training, social activities and control of physical risk factors like high blood pressure and cholesterol.

After two years, those in the intervention group had significantly improved performance on different memory measures compared with the control group, according to Miia Kivipelto, a professor of clinical geriatric epidemiology at Karolinska Institutet in Stockholm, who presented the work. The participants will continue to be followed for seven years.

Several trials in the field are testing compounds thought to reduce in the brain the amount of a protein called amyloid as preventive strategies. Clumps of the protein, known as plaques, are thought to contribute to the disease.

One Banner study expected to begin in 2015 and take nine years to complete will focus on 1,300 cognitively normal people with mutations in the ApoE4 gene, which put them at higher risk of the disease, and test two different anti-amyloid drugs, Dr. Tariot says.

There's also the 5,800-participant Tomorrow study, funded by Takeda Pharmaceutical Co. 4502.TO +0.19% and Zinfandel Pharmaceuticals Inc., to examine whether a diabetes drugs called pioglitazone may delay symptoms in the next five years in people at high risk as predicted by a combination of age and a gene called TOMM40, who are cognitively normal.

"The general feel in the field is that it's all in the timing," says Kathleen A. Welsh-Bohmer, director of the Joseph & Kathleen Bryan Alzheimer's Disease Center at Duke University, who leads the design of the neuropsychological measures used in the Tomorrow study.

While a lot of animal data and human epidemiological data showing that people who engage in healthy lifestyle practices seem to have decreased risk of Alzheimer's, it isn't clear whether they actually delay the onset of disease, say experts.

In addition, researchers want to understand specifics: how much of these activities are needed, for how long and when intervention should begin to make an impact on brain health, says Bruno Vellas, a professor at the University of Toulouse Hospital.

The goal of these types of studies is to be able to offer much more specific guidance about lifestyle activities to stave off dementia, says Dr. Vellas. "With people with cognitive decline, we must be more directive."

http://online.wsj.com/news/articles/SB20001424052702304668604580029221707863854?tesla=y&mg=reno64-wsj